"Proton Pump Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.
| Descriptor ID |
D054328
|
| MeSH Number(s) |
D27.505.519.389.848
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Proton Pump Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Proton Pump Inhibitors".
This graph shows the total number of publications written about "Proton Pump Inhibitors" by people in this website by year, and whether "Proton Pump Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 4 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 4 | 1 | 5 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 5 | 8 |
| 2010 | 5 | 2 | 7 |
| 2011 | 5 | 3 | 8 |
| 2012 | 5 | 5 | 10 |
| 2013 | 6 | 6 | 12 |
| 2014 | 3 | 2 | 5 |
| 2015 | 15 | 5 | 20 |
| 2016 | 8 | 5 | 13 |
| 2017 | 10 | 5 | 15 |
| 2018 | 11 | 4 | 15 |
| 2019 | 7 | 4 | 11 |
| 2020 | 9 | 2 | 11 |
| 2021 | 3 | 1 | 4 |
| 2022 | 1 | 9 | 10 |
| 2023 | 1 | 6 | 7 |
| 2024 | 5 | 4 | 9 |
| 2025 | 2 | 4 | 6 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proton Pump Inhibitors" by people in Profiles.
-
Gatherings in Esophagology: Innovations and Future Directions in the Diagnosis and Management of Reflux Disease. Ann N Y Acad Sci. 2026 Mar; 1557(1):e70225.
-
CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Rev Clin Pharmacol. 2026 Jan-Feb; 19(2):133-150.
-
Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens for Helicobacter pylori eradication: a systematic review and network meta-analysis. BMJ Open Gastroenterol. 2026 Jan 14; 13(1).
-
Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial). Sci Rep. 2025 Dec 18; 15(1):44105.
-
Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults. Helicobacter. 2025 Sep-Oct; 30(5):e70064.
-
Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment. Minerva Gastroenterol (Torino). 2025 Sep; 71(3):194-206.
-
Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective. BMJ Open Gastroenterol. 2025 Apr 19; 12(1).
-
Pediatric Laryngopharyngeal Reflux: Epidemiology, Clinical Presentation, Diagnosis, and Therapeutic Outcomes. Otolaryngol Clin North Am. 2025 Jun; 58(3):507-517.
-
Impact of an Electronic Medical Record Quality Improvement Intervention on Helicobacter pylori Treatment and Eradication Rates in a U.S. Hospital System. Helicobacter. 2025 Mar-Apr; 30(2):e70034.
-
Proton pump inhibitor effect on macrophage and neutrophil function: a systematic review. Front Immunol. 2024; 15:1477993.